Soares Joana Maria, Carneiro Bruno Daniel, Pozza Daniel Humberto
Department of Biomedicine, Unit of Experimental Biology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Rheumatology Service, Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos, 4990-078 Ponte de Lima, Portugal.
Int J Mol Sci. 2025 Jun 21;26(13):5971. doi: 10.3390/ijms26135971.
Temporomandibular disorders (TMDs) impact quality of life and present diagnostic and treatment challenges. Biomarkers may serve as an additional tool to support diagnosis and monitor disease progression, offering supplementary information for treatment strategies in specific and selected patients. This systematic review aimed to assess the role of biomarkers in diagnosing TMD and guiding personalized treatment. It also examined key biomarkers linked to chronic temporomandibular joint (TMJ) pain and how therapies affect biomarker levels and clinical outcomes. A comprehensive search was conducted in PubMed, Scopus, and Web of Science to identify observational and interventional studies assessing the role of biomarkers in synovial fluid/tissue, saliva, and blood. The research was registered in PROSPERO, adhered to PRISMA guidelines, and employed Cochrane Risk of Bias tools. To assess the effect, only studies examining biomarker levels were considered. A total of forty-six studies met the inclusion criteria: three randomized controlled trials were rated as having some concerns, as were most of the observational studies. Elevated levels of interleukins (1ß and 6), tumour necrosis factor alpha, and prostaglandin E2 in synovial fluid were correlated with temporomandibular joint (TMJ) inflammation. Increased matrix metalloproteinases (2, 7, and 9) indicated cartilage deterioration, while oxidative stress markers such as malondialdehyde were higher in TMD patients. Treatments including hyaluronic acid, platelet-rich plasma, and low-level laser therapy effectively reduced inflammatory biomarkers and improved symptoms. Biomarkers show potential to contribute to the understanding of pathophysiological mechanisms in TMD and may support future diagnostic and therapeutic strategies for selected patients. After high-quality studies confirm these findings, this approach will enable personalized medicine by tailoring treatments to individual patient profiles, ultimately leading to improved outcomes and quality of life.
颞下颌关节紊乱病(TMDs)会影响生活质量,并且带来诊断和治疗方面的挑战。生物标志物可作为辅助工具来支持诊断并监测疾病进展,为特定和选定患者的治疗策略提供补充信息。本系统评价旨在评估生物标志物在诊断TMD及指导个性化治疗中的作用。它还研究了与慢性颞下颌关节(TMJ)疼痛相关的关键生物标志物,以及治疗如何影响生物标志物水平和临床结果。在PubMed、Scopus和Web of Science中进行了全面检索,以识别评估生物标志物在滑液/组织、唾液和血液中的作用的观察性和干预性研究。该研究已在国际前瞻性系统评价注册库(PROSPERO)登记,遵循系统评价和Meta分析的首选报告项目(PRISMA)指南,并采用Cochrane偏倚风险工具。为评估效果,仅考虑了检测生物标志物水平的研究。共有46项研究符合纳入标准:3项随机对照试验被评为存在一些问题,大多数观察性研究也是如此。滑液中白细胞介素(1β和6)、肿瘤坏死因子α和前列腺素E2水平升高与颞下颌关节(TMJ)炎症相关。基质金属蛋白酶(2、7和9)增加表明软骨退化,而氧化应激标志物如丙二醛在TMD患者中更高。包括透明质酸、富血小板血浆和低强度激光治疗在内的治疗有效降低了炎症生物标志物并改善了症状。生物标志物显示出有助于理解TMD病理生理机制的潜力,并可能支持未来针对选定患者的诊断和治疗策略。在高质量研究证实这些发现后,这种方法将通过根据个体患者情况量身定制治疗实现个性化医疗,最终改善治疗效果和生活质量。